Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dainippon Sumitomo Allergy Drug Enters Phase I Trials

This article was originally published in PharmAsia News

Executive Summary

Dainippon Sumitomo Pharma announced that an allergic disorder agent that was jointly developed with AstraZeneca has entered Phase I trials. An immune response modifier with agonistic activity against toll-like receptor 7, the drug candidate will re-balance Th1/Th2 cells that were found shifted in allergy patients. The company hopes the compound will provide long term remission for patients with bronchial asthma and allergic rhinitis. Under the collaboration agreement, DSP will retain development and market rights in Japan, China, South Korea, and option rights to co-promote in the U.S. and major European countries. AstraZeneca will pay running royalties based on sales after the launch of the products. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts